Virginiamycin S1

Summary

Virginiamycin S1 is the streptogramin B component of the virginiamycin complex, a natural antibiotic mixture produced by Streptomyces virginiae. It is a cyclic hexadepsipeptide that inhibits prokaryotic protein synthesis. Alone it is bacteriostatic, but in combination with the type A component (virginiamycin M1) the mixture is bactericidal. The combination has been used as a growth promotant in livestock and as an agricultural antibiotic; it is closely related to quinupristin, the streptogramin B component of the approved drug quinupristin/dalfopristin (Synercid).

Mechanism of Action

Binds to the 50S ribosomal subunit at the peptidyl transferase center, blocking the exit tunnel and inhibiting elongation and translocation of peptide chains; acts synergistically with streptogramin A components (e.g., virginiamycin M1) to produce irreversible, bactericidal inhibition

Routes of Administration

Goals & Uses

• Gram-positive bacterial infection treatmentAntimicrobialModerate
• MRSA and resistant Gram-positive infectionsAntimicrobial ResistanceLow
• Livestock growth promotionVeterinary/agriculturalHigh
• Ribosomal biology research toolResearchHigh

Contraindications

• Concurrent use with drugs metabolized by CYP3A4Drug InteractionModerate
• Hypersensitivity to streptogramin antibioticsAllergyHigh

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• Arthralgia/myalgiaMusculoskeletalUncommon
• Injection site reactionsLocalCommon
• Gastrointestinal disturbanceGastrointestinalCommon

Drug Interactions

• CYP3A4 substrates (e.g., cyclosporine, tacrolimus, statins)High
• WarfarinModerate
• Chloramphenicol / lincosamidesModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Pediatric populationAgeRelative

Regulatory Status

• European UnionWithdrawnVirginiamycin combination as veterinary growth promotant banned in EU since 1999 (Regulation EC No 2821/98) due to cross-resistance concerns with quinupristin/dalfopristin
• United StatesUnapprovedNot approved as a standalone pharmaceutical in the US; virginiamycin combination used in some veterinary/agricultural contexts under USDA/FDA framework
• United KingdomUnapprovedNo approved human pharmaceutical use; agricultural use mirroring EU restrictions post-Brexit

Virginiamycin as a combination product (M1 + S1) has been used as a veterinary/agricultural growth promotant in several countries but has faced bans or restrictions in the EU due to concerns over cross-resistance with quinupristin/dalfopristin. The isolated S1 component alone is not an approved pharmaceutical agent in any major jurisdiction.

Evidence & Sources

No sources recorded yet.